Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2206 to 2220 of 7682 results

  1. Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]

    Awaiting development [GID-TA11516] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]

    Awaiting development [GID-TA11517] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]

    Awaiting development [GID-TA11560] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]

    Awaiting development [GID-TA11486] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]

    In development [GID-TA11235] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]

    Awaiting development [GID-TA11281] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292]

    Awaiting development [GID-TA11565] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]

    In development [GID-TA11500] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. RespiraSense (MT736)

      Status ...

    Medical technologies guidance
    Topic selection

  10. Cyanoacrylate glue for hernia mesh fixation (MT707)

      Status ...

    Medical technologies guidance
    Topic selection

  11. Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]

    Awaiting development [GID-TA11472] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. The Insides System chyme reinfusion system (MT682)

      Status ...

    Medical technologies guidance
    Topic selection

  13. d-NAV for optimization of personal insulin management in adults with type 2 diabetes (MT696)

      Status ...

    Medical technologies guidance
    Topic selection

  14. TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation (MT512)

      Status ...

    Medical technologies guidance
    Topic selection

  15. Lumella Pre-Eclampsia point-of-care test for assessing pre-eclampsia risk (MT687)

      Status ...

    Diagnostics guidance
    Topic selection